Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (March 2026)
28 slides from Glaukos's investor presentation, Mar 2, 2026
Slide 1: Investor Presentation March 2026
Investor Presentation MARCH 2026
Slide 2: Disclaimer
ABOUT GLAUKOS 2 © 2026 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These sta
Slide 3: We'll Go First: Innovation at the core
ABOUT GLAUKOS 3 © 2026 Glaukos Corporation WE’LL Innovation is at the core of everything we do. We push the limits of science and technology to solve unmet needs in chronic eye diseases for the benefit of patients worldwide. Dropless Therapies Challenging conventional paradigms to advance the standa
Slide 4: Best-in-Class Growth Company with Industry-Leading Pipeline
ABOUT GLAUKOS 4 © 2026 Glaukos Corporation Best-in-Class Growth Company with Industry-Leading Pipeline 13 Disclosed pipeline 12 programs Currently commercialized products Ocular Hypertension and Open-Angle Glaucoma Keratoconus Blepharitis Myopia AMD DME RVO 30% 2025 topline growth 20% 10-yr revenue
Slide 5: Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities
ABOUT GLAUKOS 5 © 2026 Glaukos Corporation Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities Fundamentally resets how keratoconus is diagnosed, managed and treated to dramatically improve patient awareness and access to effective care INTERVENTIONAL KERATOCONUS Radically improves the
Slide 6: Major Problem in Glaucoma Care: Non-Compliance with Topical Eye Drops
INTERVENTIONAL GLAUCOMA 6 © 2026 Glaukos Corporation Major Problem in Glaucoma Care: Non-Compliance with Topical Eye Drops 1 Nordstrom BL et al. Am J Ophthalmol. 2005;140(4): 598-606. % 90are non-compliant with topical drops 50~ % purposely discontinue topical drops within 6 months Patients aren’t c
Slide 7: Glaukos is Ideally Positioned to Lead the IG Paradigm Shift
INTERVENTIONAL GLAUCOMA 7 © 2026 Glaukos Corporation Glaukos is Ideally Positioned to Lead the IG Paradigm Shift OCULAR HYPERTENSION ADVANCED MODERATE MILD REFRACTORY The IG workhorse: Foundational therapy across the entire disease stage spectrum For patients who have failed surgical and medical the
Slide 8: iDose TR: Long-Duration Drug Therapy Addresses Patient Non-Compliance
INTERVENTIONAL GLAUCOMA 8 © 2026 Glaukos Corporation iDose TR: Long-Duration Drug Therapy Addresses Patient Non-Compliance Anchors securely into scleral tissue for continual elution of unique, highly concentrated travoprost directly into anterior chamber Designed to deliver up to 3 years of drug the
Slide 9: iDose TR is Just the Beginning
INTERVENTIONAL GLAUCOMA 9 © 2026 Glaukos Corporation iDose TR is Just the Beginning IG PARADIGM SLT PROCEDURAL PHARMACEUTICALS MIGS MIBS FILTRATION SURGERY Topical meds as bridge therapy • Designed to streamline insertion to help facilitate potential future in-office administration • IND amendment f
Slide 10: iStent infinite: Best-in-Class MIGS Therapy for Long-Term IOP Control
INTERVENTIONAL GLAUCOMA 10 © 2026 Glaukos Corporation iStent infinite: Best-in-Class MIGS Therapy for Long-Term IOP Control IG PARADIGM SLT PROCEDURAL PHARMACEUTICALS MIGS MIBS FILTRATION SURGERY Topical meds as bridge therapy 2012 Pioneered MIGS with iStent approval iStent technologies supported by
Slide 11: IG Represents the Next Wave for Comprehensive Ophthalmology Practices
INTERVENTIONAL GLAUCOMA 11 © 2026 Glaukos Corporation IG Represents the Next Wave for Comprehensive Ophthalmology Practices 1 Market Scope 2025 Glaucoma Surgical Device Report 2 Market Scope 2024 Glaucoma Pharmaceutical Report; includes glaucoma and OHT patients; assumes bilateral rate of 1.8x IG cr
Slide 12: IG: A Vision for the Next 10 Years
INTERVENTIONAL GLAUCOMA 12 © 2026 Glaukos Corporation Ophthalmic surgeons seek to offset continued cataract surgery pro fee reductions, helping to drive adoption and utilization of IG therapy 1 3 In-office injectable delivery of iDose and repeat administration approval can drive 2 inflection in iDos
Slide 13: Product Roadmap Underscores Extensive IG Product Depth
INTERVENTIONAL GLAUCOMA 13 © 2026 Glaukos Corporation Product Roadmap Underscores Extensive IG Product Depth PRODUCT PATIENT STATUS iStent / iStent inject / iStent inject W Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) iStent infinite Glaucoma (failed on prior therapy) FDA
Slide 14: Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities
ABOUT GLAUKOS 14 © 2026 Glaukos Corporation Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities Fundamentally resets how keratoconus is diagnosed, managed and treated to dramatically improve patient awareness and access to effective care INTERVENTIONAL KERATOCONUS INTERVENTIONAL GLAUCOM
Slide 15: Keratoconus: Debilitating, Sight-Threatening Rare Disease
INTERVENTIONAL KERATOCONUS 15 © 2026 Glaukos Corporation Keratoconus (KC): Debilitating, Sight-Threatening Rare Disease OR KC is characterized by thinning and steepening of the cornea • Typical onset in teenage years, most aggressively advancing in patients under age 30 • ~90% of cases are bilateria
Slide 16: KC: Vastly Underdiagnosed, Misdiagnosed, Undertreated Disease
INTERVENTIONAL KERATOCONUS 16 © 2026 Glaukos Corporation KC: Vastly Underdiagnosed, Misdiagnosed, Undertreated Disease 1 Kreps EO, et al. Cont Lens Anterior Eye. 2021:44(3):101 2 Based on annual Glaukos procedure volumes and internal analysis 3 Syed ZA, et al. Ophthalmology. 2024;131(8):892-901. …op
Slide 17: Transformative Epioxa Therapy Ushers in New Standard of KC Care
INTERVENTIONAL KERATOCONUS 17 © 2026 Glaukos Corporation Transformative Epioxa Therapy Ushers in New Standard of KC Care First and only FDA-approved epithelium-on treatment Incision-free, topical drug therapy catalyzed by oxygen and light Designed to slow or halt KC progression with a single adminis
Slide 18: Rare Disease: Significant Investment to Dramatically Improve KC Patient Access
INTERVENTIONAL KERATOCONUS 18 © 2026 Glaukos Corporation Rare Disease: Significant Investment to Dramatically Improve KC Patient Access Patient Education Advocacy Engagement Provider Awareness, Detection Centers & Tools Patient Service & Market Access Support Integrated IT Deployment Epioxa Sites of
Slide 19: Launch Timing for Epioxa & New Rare Disease Infrastructure
INTERVENTIONAL KERATOCONUS 19 © 2026 Glaukos Corporation Launch Timing for Epioxa & New Rare Disease Infrastructure 1Q 26 2Q 26 3Q 26 4Q 26 2027+ Go live with patient service and support hub Drug availability/launch Establish site of care network Establish payer coverage Support advocacy efforts and
Slide 20: Next Game-Changing Program: Customized, Spherical Therapy for KC
INTERVENTIONAL KERATOCONUS 20 © 2026 Glaukos Corporation WHAT IF? CUSTOMIZED, SPHERICAL THERAPY Use biomechanical modeling to deliver customized, patterned treatment that matches each patient’s unique corneal topography Use proprietary algorithm to precisely target UV energy for maximum CXL efficacy
Slide 21: Product Roadmap for Sustained Leadership in Effective KC Care
INTERVENTIONAL KERATOCONUS 21 © 2026 Glaukos Corporation Product Roadmap for Sustained Leadership in Effective KC Care PRODUCT PATIENT STATUS Photrexa (Epi-off) Keratoconus FDA Approved (2016) Epioxa (Epi-on) Keratoconus FDA Approved (2025) iLink 3rd Generation Keratoconus Phase 2 iVeena (IVMED-80)
Slide 22: Novel Eyelid Drug Delivery Platform Spearheads Entry into Anterior Segment Part D
iLUTION PLATFORM 22 © 2026 Glaukos Corporation Novel Eyelid Drug Delivery Platform Spearheads Glaukos’ Entry into Anterior Segment Part D Pharmaceuticals 1 O'Dell L, Dierker DS, Devries DK, et al. Psychosocial Impact of Demodex Blepharitis. Clin Ophthalmol. 2022;16:2979-2987 2 Publicly available mar
Slide 23: Biodegradable Implants Designed to Provide Long-Duration Efficacy
RETINA XR PLATFORM 23 © 2026 Glaukos Corporation Biodegradable Implants Designed to Provide Long-Duration Efficacy 1 Market Scope 2 Long-term Experience With Intravitreal Anti-VDGF Treatment in Patients with AMD: Analysis of IRIS Registry Database (presented at 39th Annual Meeting of the American So
Slide 24: Disrupting Paradigms with One of the Industry's Most Formidable Portfolios
ABOUT GLAUKOS 24 © 2026 Glaukos Corporation Disrupting Paradigms with One of the Industry’s Most Formidable Portfolios PRODUCT PATIENT STATUS iStent / iStent inject / iStent inject W Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) GLAUCOMA iStent infinite Glaucoma (failed on
Slide 25: Solid Financial Footing Supports Future Pipeline Delivery & Growth Plans
ABOUT GLAUKOS 25 © 2026 Glaukos Corporation Solid Financial Footing Supports Future Pipeline Delivery & Growth Plans NET SALES 1 (in millions) 2022 2023 $315 $283 $383 2024 $507 2025 GLOBAL INFRASTRUCTURE 17Countries with direct operations 300+ Global commercial personnel GROSS MARGIN2 ( 4Q 2025) 85
Slide 26: We'll Go First
WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 27: Glaukos: Transforming Vision
GLAUKOS TRANSFORMING VISION
Slide 28: Appendix: GAAP to Non-GAAP Reconciliation - 4Q 2025
ABOUT GLAUKOS 28 © 2026 Glaukos Corporation Appendix 4Q 2025 GAAP Amort. of Dev Non-recurring Impairment 4Q 2025 Non-GAAP Gross Margin Tech Intangibles, Dev IP, and Dist Rights Write-down of Inventory with Transition from Photrexa to Epioxa Gross Margin Net Sales $ 143,121 $ 143,121 Cost of Sales $